Company: Sanofi
Tags: territory, pipeline
Dupixent access for atopic dermatitis in commercial lives is genuinely strong right now. Medicare Part D is still more complicated but we've gotten better processes. The challenge is the growing number of patients on Rinvoq or Cibinqo who switched from Dupixent — that's real and it's happening. Not because Dupixent failed but because JAK inhibitor reps are doing a better job at re-engaging lapsed patients. I think Dupixent's advantage in safety profile is still meaningful for a lot of patients and prescribers, especially in pediatrics. But we can't coast. The IL-4/IL-13 message alone isn't eno
27 upvotes · 0 comments